The second shot of simepaglutide also requires venting.
Simeglutide is a long-acting insulin-like peptide-1 and can be used in adults with type 2 diabetes who continue to have substandard blood glucose after treatment with oral hypoglycemic agents, such as sulfonylureas or metformin, on the basis of exercise and dietary control. It is contraindicated in patients who are hypersensitive to the active ingredient of the drug or any excipients in the product, have a history of medullary thyroid carcinoma or a family history of the disease.
Each time you need to exhaust the air before treatment with simethicone, so the second hit of simethicone is also required to exhaust the air. Adverse reactions such as nausea, vomiting, diarrhea, hypoglycemia, diabetic retinopathy, and increased heart rate may occur after administration.
Patients who need to use simethicone should be treated under a doctor’s supervision.